Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | — |
The patient took all four capsules of Vivotif every day instead of every other day; Case reference number US-BN-2025-001714 is a spontaneous case report initially received from a pharmacist via Bavarian Nordic (reference number: CASE-000319) on 17-Oct-2025 and concerns a 66-year-old male patient. The patient's relevant medical history and concomitant medications were not provided. On unspecified dates, the patient took all four doses of Vivotif vaccine (batch number: unknown) at an unknown dose, route, or site of administration for an unknown indication. The patient took Vivotif every day instead of every other day (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 66-year-old male patient took all four doses of Vivotif vaccine for an unknown indication. The patient took Vivotif every day instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 66-year-old male patient took all four doses of Vivotif vaccine for an unknown indication. The patient took Vivotif every day instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.